July 23, 2025

Predicting Symptomatic Cardiotoxicity in HER2-Positive Breast Cancer Patients Treated with Trastuzumab: Insights from a Brazilian Real-World Cohort

WAWilson Eduardo Furlan Matos AlvesHospital de Câncer de Barretos MOMarco Antônio de OliveiraInstituto Butantan TATestori AlbertoSSM Health Rehabilitation Hospital

Key Points

9.9% of patients experienced symptomatic cardiotoxicity during Trastuzumab treatment.
Clinical monitoring revealed systolic ventricular dysfunction in 16.7% of patients.
Key risk factors include early LVEF drop, diastolic dysfunction, and high anthracycline doses above 240 mg/m².
Two predictive models for symptomatic cardiotoxicity presented strong outcomes, with AUC values of 0.782 and 0.763 for LVEF drop cutoffs.

Abstract

Abstract Background Cardiotoxicity is a known adverse effect of Trastuzumab treatment. Early detection through regular cardiac imaging is crucial to prevent its progression and ensure reversibility. However, recent studies question the current cardiac monitoring approach during Trastuzumab use. Symptomatic cardiotoxicity is infrequent, and interrupting treatment based solely on imaging-assessed LVEF decline might compromise effectiveness and reduce survival. Therefore, identifying risk factors for symptomatic cardiotoxicity could enable risk stratification and guide cardioprotective measures, potentially preventing unnecessary treatment interruptions and improving outcomes. Methods We retrospectively analyzed real-world data from 131 women with HER2 + breast cancer to evaluate the occurrence of symptomatic cardiotoxicity, defined by NYHA functional classes 2, 3, or 4, during Trastuzumab treatment. Cardiac monitoring involved Equilibrium Radionuclide Angiocardiography (ERNA) to assess left ventricular systolic dysfunction, specifically a > 10 percentage point decrease in LVEF from baseline to a value below the normal limit (p = 0.231). In multivariate logistic regression analysis, baseline diastolic dysfunction, a cumulative anthracycline dose greater than 240 mg/m2, and an early LVEF drop were identified as risk factors associated with the occurrence of symptomatic cardiotoxicity. Utilizing these variables, two predictive models for symptomatic cardiotoxicity were proposed. The models yielded an AUC of 0.782 (p = 0.001) for an LVEF drop cutoff of 15%, and an AUC of 0.763 (p = 0.006) for an LVEF drop cutoff of 7%. Conclusion Symptomatic cardiotoxicity occurred in 9.9% of evaluated patients. Baseline diastolic dysfunction, a cumulative anthracycline dose greater than 240 mg/m2, and an early LVEF drop were identified as risk factors for developing symptomatic cardiotoxicity during Trastuzumab use.

AI에게 질문

Bookmark

View Full Paper